相关实验视频

Updated: Jun 4, 2025

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

新的治疗方法针对中枢神经系统以外的5-HT7受体

Melis Kilic¹, Zeynep Karakoy², Hamza Halici³

¹Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.

Journal of receptor and signal transduction research

|January 4, 2025

概括

血清素 (5-HT) 和它的5-HT7受体在大脑中至关重要,并且越来越多地被认为在中枢神经系统 (CNS) 外的疾病中的作用. 需要进一步的研究才能充分理解这些外围功能.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
病理学病理学病理学

背景情况:

血清素 (5-HT) 是一个关键的神经递质,调节中枢神经系统功能,如睡眠和食欲.
5-HT7受体通常存在于中枢神经系统区域,但也在外围系统中表达.
新出现的证据表明,5-HT7受体参与了中枢神经系统以外的各种病理状况.

研究的目的:

审查目前对超出中枢神经系统的5-HT7受体作用的理解.
强调5-HT7受体与中枢神经系统以外的疾病和生理系统的关联.
为了强调对这些外围功能的进一步研究的需要.

主要方法:

临床,基础,体内和体外研究的综合文献综述.
分析着重于非中枢神经系统组织中5-HT7受体表达和功能的研究.
综合了与疾病状态和影响5-HT7受体的细胞变化相关的发现.

主要成果:

5-HT7受体与中枢神经系统以外的各种生理系统和疾病有关.
5-HT7受体的表达水平可以增加或减少,以应对这些条件下的细胞变化.
研究表明,外围5-HT7受体活性越来越重要.

结论:

5-HT7受体在中枢神经系统以外的生理和病理过程中发挥着重要的,但尚未被充分探索的作用.
了解这些外围作用对于开发新型治疗策略至关重要.
需要进行更广泛的研究,以阐明外围的5-HT7受体功能的全部范围.

关键词:

血清激素 (5-HT),5-HT7 的使用.周围组织周围组织

更多相关视频

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

相关概念视频

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Adrenergic Agonists: Indirect-Acting Agents

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...